Építés alatt – nem éles oldal
Belépés

NCT05849038Toboroz2. fázis

Inflammation and Depression in People With HIV

The Role of Inflammation in Central Nervous System (CNS) Mechanisms of Anhedonia and Psychomotor Slowing in Depressed People With HIV

Forrás: ClinicalTrials.gov · Utoljára frissítve: 2026. máj. 28.

Következő lépések

Rövid összefoglaló (regiszter, angolul)

The purpose of this 10-week, double-blind, placebo-controlled study is to determine whether inflammation impacts reward and motor neural circuitry to contribute to depressive symptoms like anhedonia and psychomotor slowing in people with Human Immunodeficiency Virus (HIV) and depression. Sixty male and female patients with HIV who have depression, anhedonia and high inflammation and are stable on effective treatment for their HIV will be randomized to receive either the anti-inflammatory drug baricitinib or a placebo for 10 weeks. Participants will complete lab tests, medical and psychiatric assessments, neurocognitive testing, functional MRI (fMRI) scans, and optional spinal taps as part of the study.

Állapot (regiszter)
Toboroz
Fázis (regiszter)
2. fázis
Vizsgálattípus
Beavatkozással járó
Résztvevők száma
60 (tervezett)
Első benyújtás
2023. ápr. 27.
Kezdés
2023. dec. 11.
Elsődleges befejezés
2027. nov.
Fő szponzor
Emory University
Betegségek
HIV-fertőzés
NCT-szám
NCT05849038

Mit vállalsz

  • Vizsgálat típusa: Beavatkozással járó · 2. fázis
  • Tervezett résztvevők: 60
  • 2023. dec. 11. és az elsődleges befejezés (2027. nov.) között
  • 2 helyszín, 1 országban
  • Vizitek és vizsgálatok: kérdezd a vizsgálat csapatát, a regiszter nem sorolja fel őket

A(z) ClinicalTrials.gov regisztermezőiből összeállítva. A vizsgálat felépítését írja le.

Ki nem vehet részt

Szó szerint a(z) ClinicalTrials.gov forrásból, témák szerint csoportosítva. Hogy ki vehet részt, azt csak a vizsgálat csapata dönti el.

Korábbi kezelés

  • Untreated latent tuberculosis infection (which will be screened for prior to entry)
  • Having taken the following immunosuppressive medications within the past 6 months:
    • Oral corticosteroids
    • Biologic treatments such as etanercept, infliximab, certolizumab, adalimumab, golimumab, tocilizumab, abatacept, Ustekinumab, ixekizumab, secukinumab, or anakinra
    • Cyclophosphamide (or any other cytotoxic agent), belimumab, or anifrolumab (or another anti-interferon (IFN) therapy)
    • Rituximab, any other B cell depleting therapies, or intravenous immunoglobulin (IVIg)
    • any Janus kinase (JAK) inhibitor
  • Major surgery within 8 weeks prior to screening or will require major surgery during the study
  • Current or recent (<4 weeks prior to randomization) clinically serious viral (including coronavirus disease 2019 (COVID-19)), bacterial, fungal, or parasitic infection or any other active or recent infection
  • Symptomatic herpes zoster infection within 12 weeks prior to randomization
  • A positive urine drug screen for illicit drugs at any time during the study excluding marijuana
  • Chronic use of glucocorticoid containing medications or minocycline within 2 weeks of baseline or at any time during the study

Más betegség

  • History of progressive multifocal leukoencephalopathy
  • History of deep venous thrombosis
  • Hematologic malignancies including lymphoma and leukemia
  • History of disseminated/complicated herpes zoster (for example, ophthalmic zoster or CNS involvement)
  • Positive test for hepatitis B virus (HBV) defined as:
    • positive for hepatitis B surface antigen (HBsAg), or
    • positive for hepatitis B core antibody (HBcAb) and positive for hepatitis B virus deoxyribonucleic acid (HBV DNA)
  • Hepatitis C virus (HCV) infection (hepatitis C antibody-positive and HCV ribonucleic acid [RNA]-positive)
  • History of any (non-mood-related) psychotic disorder; active psychotic symptoms of any type; substance abuse/dependence within 6 months of study entry, as determined by severe combined immunodeficiency (SCID)
  • An active eating disorder or antisocial personality disorder
  • History of dementia
  • Failure of more than 2 antidepressant trials (at least 6 weeks at recommended dose) in the current episode or 5 antidepressant trials lifetime

Laborértékek

  • Significant hematological abnormalities at screening (ANC < 1500, Hgb<10, platelet< 100,000)
  • Cardiovascular disease:
    • Coronary artery disease or history of myocardial infarction
    • Congestive heart failure with left ventricular ejection fraction ≤40% per American Heart Association guidelines
    • Stroke history
  • Any of the following specific abnormalities on screening laboratory tests:
    • alanine transaminase (ALT) or aspartate aminotransferase (AST) >2 x upper limits of normal (ULN)
    • alkaline phosphatase (ALP) ≥2 x ULN
    • total bilirubin ≥1.5 x ULN (with the exception of patients on atazanavir, who must have total bilirubin <2 x ULN)
  • Chronic kidney disease with estimated glomerular filtration rate (eGFR) <40 mL/min/1.73 m\^2

Életkor

  • < 18 years of age or > 65 years of age

Egyéb

  • Pregnancy or breastfeeding
  • Symptomatic herpes simplex at the time of randomization
  • Cirrhosis of the liver from any cause
  • An active suicidal plan as determined by a score >3 on item #3 on the Hamilton Rating Scale for Depression (HAM-D)
  • Any contraindication for MRI scanning
  • BMI >42 (to exclude severe obesity) or at the investigator's discretion based on the patient's ability to fit in the MRI scanner

Kiket keres a vizsgálat

  • HIV infected on continuous antiretroviral therapy (ART) with plasma HIV RNA <200 copies/ml for at least 12 months (on at least two previous clinic visits and confirmed at screening)
  • Current cluster of differentiation 4 (CD4+) > 350 cells/microliter for at least twelve months (on at least two previous clinic visits and confirmed at screening)
  • A primary diagnosis of Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) major depression, current, or Bipolar, depressed type as diagnosed by the SCID-V
  • Score of ≥10 on the 9-item Patient Health Questionnaire (PHQ-9)
  • Off all antidepressant or other psychotropic therapy (e.g. mood stabilizers, antipsychotics, and sedative hypnotics) for at least 4 weeks (8 weeks for fluoxetine) or on a stable psychotropic regimen for at least 4 weeks prior to baseline visit
  • Significant anhedonia as reflected by a score ≥ 2 on item #1 of the PHQ-9
  • CRP≥2mg/L
  • Women of reproductive age will have a negative serum pregnancy test at study entry and both men and women must agree to adequate contraception while

Életkor a regiszterben: 18 év – 65 év · Nem: nők és férfiak · Egészséges önkénteseket nem fogad

A teljes feltétellista: ClinicalTrials.gov

Helyszínek (2)

Helyszínek a regiszter sorrendjében. Ha a profilodba mented a városodat, távolság szerint rendeződnek.

HelyszínVárosOrszágHelyszín állapota
Grady Memorial HospitalAtlantaEgyesült ÁllamokToboroz
Emory University HospitalAtlantaEgyesült ÁllamokToboroz

Te vagy a koordinátor? Erősítsd meg az adatokat

Ez az oldal tájékoztatás, nem orvosi tanács. Bármely vizsgálatról az orvosoddal beszélj.